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surgical patients and 163 (39.8%) of medical patients.  Con-
clusions: The data showed that VTE prophylaxis was under-
utilized in high-risk hospitalized patients. We recommend 
that active measures should be implemented in acute care 
centres in these Arabian Gulf countries to ensure identifica-
tion of patients at risk of VTE and institute the appropriate 
prophylaxis. 
 
Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Venous thromboembolism (VTE) prophylaxis in 
acute care medical centres has been proven to be effective 
in reducing the rate of VTE in high-risk patients  [1, 2] . 
Several post-mortem studies have shown a significant 
hospital VTE-related mortality up to 10%, thereby mak-
ing VTE one of the main causes of death in hospitalized 
patients  [3–5] . Awareness of potential risk factors that put 
hospitalized patients at risk of VTE and implementation 
of evidence-based thromboprophylactic measures in 
these patients have been published in several guidelines 
 [6–10] . Despite the publication of these guidelines, some 
of them updated annually, a large number of practicing 
physicians and surgeons still underestimate VTE risk and 
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 Abstract 
 Objectives: To assess the prevalence of venous thromboem-
bolism (VTE) risk in acutely ill surgical and medical patients 
in selected acute care centres in the Arabian Gulf States, and 
to determine the proportion of at-risk patients who received 
effective prophylaxis in accordance with 2004 American Col-
lege of Chest Physicians (ACCP) guidelines.  Materials and 
Methods: Eight hospitals from 3 countries (Kuwait, Kingdom 
of Saudi Arabia, and United Arab Emirates) contributed to 
the global ENDORSE (Epidemiological International Day for 
the Evaluation of Patients at Risk for Venous Thromboembo-
lism in the Acute Hospital Care Setting) study. Medical re-
cords were reviewed for all the in-patients aged  6 40 years 
admitted to medical wards, and in patients aged  6 18 admit-
ted to surgical wards. The VTE risk and recommended pro-
phylaxis were assessed according to the 2004 ACCP guide-
lines.  Results: Of 1,291 evaluable patients, 801 were consid-
ered at risk of VTE; 391 (48.8%) surgical patients and 410 
(51.2%) medical patients. Of the 801 patients, 322 (40.2%) re-
ceived ACCP-recommended VTE prophylaxis; 159 (40.7%) of 
 Received: June 2, 2011 
 Accepted: April 4, 2012 
Published online: June 8, 2012
 Faisal Alsayegh 
 Department of Medicine 
 Faculty of Medicine, Kuwait University 
 PO Box 24923, Safat 13110 (Kuwait) 
 Tel. +965 9967 8870, E-Mail fsayegh63   @   gmail.com 
 © 2012 S. Karger AG, Basel
1011–7571/12/0216–0522$38.00/0 
 Accessible online at:
www.karger.com/mpp 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ity
 o
f M
as
sa
ch
us
et
ts
&#
44
;W
or
ce
st
er
14
6.
18
9.
22
8.
13
0 
- 1
2/
15
/2
01
4 
3:
53
:1
5 
PM
 Gulf ENDORSE Med Princ Pract 2012;21:522–528 523
thus implement inadequate VTE prophylaxis practices 
 [11–13] .
 The ENDORSE (Epidemiologic International Day for 
the Evaluation of Patients at Risk of Venous Thrombosis 
in the Acute Hospital Care Setting) study was the first 
published global multicentre cross-sectional study that 
explored the percentage of acute care hospitalized pa-
tients at risk of VTE at any given time. It also looked into 
adherence to strict VTE prophylaxis practices according 
to risk stratification in surgical and medical patients as 
published in the American College of Chest Physicians 
(ACCP) guidelines  [14] .
 The need to explore VTE risk estimation and adequa-
cy of VTE prophylactic strategies in Arabian Gulf coun-
tries is of great importance since data in this area are rare. 
There is only one such study  [15] , which explored VTE 
risk factors, its rate in surgical and medical wards and the 
appropriateness of using pharmacologic anticoagulation. 
This study showed a significant VTE rate in both surgical 
and medical patients. In addition, there was inappropri-
ate utilization of pharmacologic anticoagulants in pa-
tients with established VTE  [15] .
 The objectives of this study were to use the global
ENDORSE study to determine the prevalence of patients 
at VTE risk in selected acute care hospital settings in the 
Arabian Gulf region; to find the proportion of patients at 
VTE risk that received thromboprophylaxis in accor-
dance with ACCP 2004 guidelines  [7] .
 Materials and Methods 
 The methodology of the study has been described in the glob-
al ENDORSE publication  [14] . Briefly, hospital selection was done 
randomly from authoritative lists of acute care centres in 3 Ara-
bian Gulf countries: Kuwait, Kingdom of Saudi Arabia (KSA) and 
United Arab Emirates (UAE). Hospitals with more than 50 beds 
that admit patients with acute and chronic medical disorders as 
well as scheduling routine surgical procedures were considered 
eligible for inclusion in the study. Approval of the local hospital 
authorities was obtained before collecting the data. Signed patient 
consent was not required.
 Patients’ data, including demographics, diagnosis on admis-
sion, VTE risk factors, factors associated with risk of bleeding, 
duration of hospital stay and VTE prophylaxis used including the 
dosage (in accordance with ACCP guidelines), were extracted 
from the patients’ medical records. Standardized case report 
forms were used by trained medical personnel to extract the data.
 The survey included patients who were hospitalized in an eli-
gible ward at the time of data collection. One day was considered 
adequate for each eligible ward to complete the data collection 
forms. The eligibility criteria included those patients who are 
 6 40 years of age in eligible medical wards and patients aged  6 18 
in eligible surgical wards based on ENDORSE recommendation 
 [14] . In addition, patients assessed for VTE risk included acutely 
ill medical patients, patients hospitalized for major trauma or un-
dergoing a major surgical procedure requiring general or epidu-
ral anaesthesia for at least 45 min. VTE risk assessment in surgical 
patients was classified as being at highest, high, moderate or low 
risk for VTE. Data on VTE thromboprophylaxis that had been 
collected were only those that followed ACCP 2004 guidelines. 
However, thromboprophylaxis duration could not be assessed 
due to the cross-sectional nature of the study.
 Patients were considered ineligible for VTE thromboprophy-
laxis if they presented or were at risk of the following: intracra-
nial haemorrhage, liver impairment, bleeding at hospital admis-
sion, an active peptic ulcer, and known bleeding disorder. The 
selection algorithm of eligible patients and the number of the 
evaluable patients in surgical and medical wards are shown in 
 figure 1 .
 Statistical analyses of the global ENDORSE report were used 
in this study  [14] .
 Results 
 Of the 1,291 evaluable patients in the 3 countries, 801 
(62%) were considered to be at risk of VTE. Patient char-
acteristics and indications of admission in surgical and 
medical wards are listed in  table 1 .
275 patients excluded:
   · 8 missing hospital charts
   · 209 too young (age <18 for
     surgical; age <40 for medical)
   · 3 admitted for VTE
   · 3 admitted for diagnostic test
   · 5 minor operations
   · 13 should be in excluded 
     wards
   · 34 missing key information
1,291 evaluable patients
Patients on
surgical wards
643 (49.8%)
Patients on
medical wards
648 (50.2%)
377 empty beds in eligible wards
1,566 patients in
eligible wards
2,286 beds in ineligible wards
1,943 beds in
eligible wards
4,229 beds in 8 randomly
selected hospitals
 Fig. 1. Selection of the study population. 
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 Several VTE risk factors were identified that were 
present prior to hospital admission, and those acquired 
during hospitalization. Immobility, cardiac failure and 
chronic lung disease were the most common risk factors 
prior to admission, whereas immobilization, intensive 
care unit/coronary care unit admission and mechanical 
ventilation were among the common acquired factors 
during hospitalization ( table 2 ).
 The most common contraindication for pharmaco-
logical prophylaxis in surgical patients was non-steroidal 
anti-inflammatory drugs, while in medical patients, it 
was the use of aspirin and renal impairment. There were 
also differences in the use of aspirin and non-steroidal 
anti-inflammatory drugs among the countries. In Ku-
wait, aspirin was more commonly used in all admitted 
patients as compared to the KSA and UAE, whereas non-
Table 1.  Characteristics and reasons for hospitalization of eligible patients
Kuwait, 
n (%)
KSA,
n (%)
UAE,
n (%)
Total,
n (%)
Patients characteristics
Number of eligible patients 271 (33.8) 284 (35.5) 246 (30.7) 801 (100)
Surgical 74 (27.3) 192 (67.6) 125 (50.8) 391 (48.8)
Medical 197 (72.7) 92 (32.4) 121 (49.2) 410 (51.2)
Male 153 (56.5) 209 (73.6) 171 (69.5) 533 (66.5)
Age (median), years 61 50 52
Body mass index (median) 26.6 25.5 25.5
Hospital admission to survey (median), days 7 14 5
Medical reasons for hospitalization
Acute heart failure (NYHA class III or IV) 37 (13.7) 26 (9.2) 37 (15.0) 100 (12.5)
Ischaemic stroke 19 (7.0) 20 (7.0) 20 (8.1) 59 (7.3)
Haemorrhagic stroke 9 (3.3) 4 (1.4) 6 (2.4) 19 (2.4)
Other cardiovascular disease 46 (17.0) 55 (19.4) 97 (39.4) 198 (24.7)
Haematologic disease 4 (1.5) 5 (1.8) 3 (1.2) 12 (1.5)
Acute noninfectious respiratory disease 38 (14.0) 12 (4.2) 6 (2.4) 56 (7.0)
Pulmonary infection 102 (37.6) 22 (7.7) 41 (16.7) 165 (20.6)
Malignancy (active) 3 (1.1) 5 (1.8) 7 (2.8) 15 (2.3)
Infection (non-respiratory) 45 (16.6) 32 (11.3) 11 (4.5) 88 (11.0)
Rheumatologic or inflammatory 2 (0.7) 0 13 (5.3) 15 (2.3)
Neurologic 12 (4.4) 21 (7.4) 18 (7.3) 51 (6.4)
Renal 20 (7.4) 18 (6.3) 29 (11.8) 67 (8.4)
Endocrine/metabolic 16 (5.9) 48 (16.9) 76 (30.9) 140 (17.5)
GI/hepatobiliary 16 (5.9) 12 (4.2) 9 (3.7) 37 (4.6)
Other medical condition 23 (8.5) 7 (2.5) 45 (18.3) 75 (9.4)
Surgical reasons for hospitalization
Hip replacement 0 5 (2.6) 1 (0.8) 6 (1.5)
Knee replacement 0 0 7 (5.6) 7 (1.8)
Hip fracture 0 8 (4.2) 5 (4.0) 13 (3.3)
Curative arthroscopy 0 0 1 (0.8) 1 (0.3)
Other orthopaedic trauma 16 (21.6) 40 (20.8) 36 (28.8) 92 (23.5)
Colon/small bowel 8 (10.8) 12 (6.3) 9 (7.2) 29 (7.4)
Rectosigmoid 0 0 0 0 (0)
Gastric 2 (2.7) 2 (1.0) 4 (3.2) 8 (2)
Hepatobiliary 11 (14.9) 1 (0.5) 3 (2.4) 15 (3.8)
Urologic 1 (1.4) 7 (3.6) 3 (2.4) 11 (2.8)
Vascular 3 3 (1.6) 0 6 (1.5)
Thoracic 1 (1.4) 1 (0.5) 0 2 (0.5)
Gynaecologic 0 0 8 (6.4) 8 (2)
Other major surgery 12 (16.2) 36 (18.8) 27 (21.6) 75 (19.2)
Admitted with major trauma but surgery not done 20 (27.0) 77 (40.1) 21 (16.8) 118 (30.2)
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steroidal anti-inflammatory drugs were more commonly 
used in the KSA as compared to Kuwait and the UAE 
( table 3 ).
 Pharmacological prophylaxis was the most frequently 
used method of prophylaxis in surgical and medical pa-
tients. Mechanical prophylaxis was a less commonly used 
method. Graduated compression stockings were the pre-
ferred method of mechanical prophylaxis especially in 
surgical wards ( table 4 ).
 Of the 801 patients at risk of VTE, only 322 (40.2%) 
received ACCP-recommended prophylaxis. The overall 
use of VTE prophylaxis in high-risk patients in each 
country and in surgical and medical departments is given 
in  table 5 .
 Discussion 
 Because only 40.2% of high-risk patients received
ACCP-recommended VTE prophylaxis, VTE prophylax-
is was underutilized in the participating centres in the 
Arabian Gulf region. This finding is lower than approxi-
mately 50% reported in the worldwide utilization of VTE 
prophylaxis in the ENDORSE study  [14] . In addition, 
there was no significant difference between surgical and 
medical patients in utilizing VTE prophylaxis because 
39.8% surgical patients and 40.7% medical patients at 
high risk received ACCP-recommended prophylaxis in 
contrast to the global ENDORSE findings reporting that 
more surgical than medical patients received VTE pro-
phylaxis  [14] .
 When we examine the data more closely by country, 
the utilization of VTE prophylaxis in the KSA in high-
risk medical patients was 62%, higher than in Kuwait 
(33.5%) and the UAE (33.1%). In fact, it is higher than the 
average global result in medical patients, which was re-
ported as 40%  [14] . On the other hand, more surgical pa-
tients at risk of VTE received ACCP-recommended pro-
phylaxis in Kuwait (58.1%) as compared to the KSA 
(32.30%) and UAE (43.2%). These results seem to indicate 
that a large proportion of practicing physicians and sur-
geons in the Arabian Gulf area lack the awareness and 
knowledge of already published evidence-based guide-
lines on everyday practice of VTE prophylaxis. It may 
also indicate the existence of a significant number of pa-
tients with contraindications to pharmacologic prophy-
laxis in this series that lead to hesitancy of health care 
providers in initiating pharmacologic prophylaxis ( ta-
Table 2. R isk factors for VTE prior to and during hospital admission
Kuwait 
n (%)
(n = 271)
KSA 
n (%)
(n = 284)
UAE
n (%)
(n = 246)
Total 
n (%)
(n = 801)
Conditions present prior to hospital admission
Previous VTE 5 (1.8) 2 (0.7) 3 (1.2) 10 (1.2)
Thrombophilia (laboratory documented) 0 0 0 0 (0)
Varicose veins or venous insufficiency 8 (3.0) 0 0 8 (1)
Postmenopausal hormone replacement therapy 1 (0.4) 0 0 1 (0.1)
Chronic pulmonary disease 47 (17.3) 17 (6.0) 10 (4.1) 74 (9.2)
Long-term immobility 46 (17.0) 16 (5.6) 21 (8.5) 83 (10.3)
Pregnancy (within 3 months) 0 0 9 (3.7) 9 (1.1)
Obesity (based on physician’s note) 42 (15.5) 10 (3.5) 14 (5.7) 66 (8.2)
Contraceptives 3 (1.1) 0 0 3 (0.3)
Chronic heart failure 27 (10.0) 22 (7.7) 30 (12.2) 79 (9.8)
Additional risk factors for VTE during hospital admission
Admitted to ICU/CCU 123 (45.4) 83 (29.2) 70 (28.5) 276 (34.5)
Central venous catheter 67 (24.7) 28 (9.9) 42 (17.1) 137 (17.1)
Mechanical ventilation 54 (19.9) 42 (14.8) 67 (27.2) 163 (20.3)
Immobile with bathroom privileges 63 (23.2) 23 (8.1) 72 (29.3) 158 (19.7)
Complete immobilization 122 (45.0) 145 (51.1) 145 (58.9) 412 (51.4)
Cancer therapy 1 (0.4) 1 (0.4) 1 (0.4) 3 (0.4)
Heparin-induced thrombocytopenia 1 (0.4) 1 (0.4) 1 (0.4) 3 (0.4)
I CU = Intensive care unit; CCU = coronary care unit.
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Table 3. C ontraindications to anticoagulation
Kuwait, 
n (%)
(n = 271)
KSA, 
n (%)
(n = 284)
UAE, 
n (%)
(n = 246)
All surgical
wards, n (%)
(n = 391)
All medical
wards, n (%)
(n = 410)
Total, 
n (%)
(n = 801)
Significant renal impairment 43 (15.9) 18 (6.3) 34 (13.8) 17 (4.3) 78 (19) 95 (11.9)
Intracranial haemorrhage 14 (5.2) 15 (5.3) 10 (4.1) 31 (7.9) 8 (2) 39 (4.9)
Low platelet count (<100,000/l) 9 (3.3) 3 (1.1) 3 (1.2) 6 (1.5) 9 (2.2) 15 (2.3)
Known bleeding disorder1 0 0 3 (1.2) 1 (0.3) 2 (0.5) 3 (0.3)
Hepatic impairment (clinically relevant) 13 (4.8) 4 (1.4) 4 (1.6) 5 (1.3) 16 (3.9) 21 (2.6)
Bleeding at hospital admission 7 (2.6) 8 (2.8) 7 (2.8) 12 (3) 10 (2.4) 22 (2.7)
Active gastroduodenal ulcer 4 (1.5) 3 (1.1) 2 (0.8) 3 (0.8) 6 (1.5) 9 (1.1)
Aspirin on admission 116 (42.8) 47 (16.5) 73 (29.7) 29 (7.4) 207 (50.5) 236 (29.5)
NSAID on admission (excluding aspirin) 24 (8.9) 57 (20.1) 24 (9.8) 80 (20.4) 25 (6.1) 105 (13.1)
N SAID = Nonsteroidal anti-inflammatory drug. 1 Congenital or acquired.
Table 4. V TE prophylaxis ordered during hospital admission
Kuwait, 
n (%)
(n = 271)
KSA, 
n (%)
(n = 284)
UAE, 
n (%)
(n = 246)
All surgical
wards, n (%)
(n = 391)
All medical
wards, n (%)
(n = 410)
Total, 
n (%)
(n = 801)
LMWH 61 (22.5) 62 (21.8) 82 (33.3) 124 (31.7) 81 (19.8) 205 (25.6)
UH 43 (15.9) 130 (45.8) 9 (3.6) 104 (26.6) 78 (19) 182 (22.7)
VKA 5 (1.8) 2 (0.7) 5 (2) 4 (1) 8 (2) 12 (1.5)
Fondaparinux 0 0 0 0 0 0
Others 0 0 0 0 0 0
Mechanical prophylaxis
IPC 9 (3.3) 0 10 (4.1) 11 (2.8) 8 (2) 19 (2.4)
Foot pump 0 0 0 0 0 0
GCS 25 (9.2) 11 (3.9) 9 (3.7) 32 (8.2) 13 (3.2) 45 (5.6)
T he IPC, foot pump and GCS were used separately in patients who had contraindications to anticoagulant based on the treating 
physician’s decision. LMWH = Low-molecular-weight heparin; UH = unfractionated heparin; VKA = vitamin K antagonists; IPC = 
intermittent pneumatic compression; GCS = graduated compression stocking.
Table 5. P roportion of high-risk patients who received VTE prophylaxis according to ACCP guidelines by country and department
Kuwait, n (%) KSA, n (%) UAE, n (%) Total, n (%)
Prophylaxis according to ACCP 109 (40.2) 119 (41.9) 94 (38.2) 322 (40.2)
Surgical 43 (58.1) 62 (32.3) 54 (43.2) 159 (40.7)
Medical 66 (33.5) 57 (62.0) 40 (33.1) 163 (39.8)
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ble 3 ). Equally important, there was also a lack of unified 
VTE risk assessment guidelines in the medical centres in 
the 3 participating Arabian Gulf countries. Thus, region-
al efforts should be carefully planned to raise awareness 
among health care professionals through implementa-
tion of educational programmes and adoption of manda-
tory VTE risk stratification charts in the wards.
 Unfractionated heparin and low-molecular-weight 
heparin were the commonest forms of pharmacologic 
prophylaxis that were used in the Arabian Gulf States ( ta-
ble  4 ). There was a preference towards unfractionated 
heparin over low-molecular-weight heparin in KSA hos-
pitals. In addition, unfractionated heparin was the com-
monly used pharmacologic prophylaxis in the UAE. The 
preferable use of unfractionated heparin has many pos-
sible explanations that include drug availability because 
of its cheap price, longer experience, and availability of a 
specific antidote to unfractionated heparin. Graduated 
compression stocking was used more often than inter-
mittent pneumatic compression because of the limited 
availability of intermittent pneumatic compression ma-
chines on the wards. In addition, foot pumps were never 
reported to be utilized in the region. The effectiveness of 
mechanical VTE prophylaxis alone or in combination 
with pharmacologic prophylaxis has been shown in many 
studies to be the recommended method in high-risk pa-
tients as published in guidelines  [12, 16–18] . Mechanical 
prophylaxis was rarely used in high-risk patients in this 
study. This underutilization of mechanical prophylaxis 
supports the notion that more is needed toward raising 
the awareness of using different forms of VTE prophy-
laxis when a contraindication to anticoagulants is indi-
cated  [17–19] .
 There are several limitations to this ENDORSE study. 
Only 8 centres participated in the study and this may not 
be representative of thromboprophylaxis practices in the 
other medical centres. The data were obtained from the 
medical records rather than from direct interview with 
the patients. Since the ENDORSE study was a cross-sec-
tional study, hence, long-term follow-up on adherence
of health care providers to published VTE prophylaxis 
guidelines was not assessed.
 Conclusion 
 The findings of the ENDORSE study in the 3 Arabian 
Gulf States showed that VTE prophylaxis was underuti-
lized in surgical and medical patients at risk of VTE. We 
therefore recommend that regional efforts should be ini-
tiated to raise awareness of VTE risk and ensure that at-
risk patients receive appropriate prophylaxis through 
mandatory hospital-based strategies, and implementa-
tion of evidence-based guidelines.
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